Effects of 2-year cocoa extract supplementation on inflammaging biomarkers in older US adults: findings from the COcoa Supplement and Multivitamin Outcomes Study randomised clinical trial
- 29 August 2025
- journal article
- research article
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 54 (9)
Abstract
Objective: To examine the long-term effect of cocoa flavanols on inflammaging biomarkers in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS). Methods: COSMOS is a large, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial testing the effects of a cocoa extract supplement (containing 500 mg cocoa flavanols/day, including 80 mg (−)-epicatechin) among women aged ≥65 years and men aged ≥60 years. This ancillary study measured five widely used serum inflammaging biomarkers, including three pro-inflammatory markers (high-sensitivity C-reactive protein [hsCRP], interleukin-6, tumour necrosis factor-α), one anti-inflammatory cytokine (interleukin-10) and one pleotropic cytokine (interferon-γ [IFN-γ]) in a random sample of 598 participants with biospecimens collected at baseline, Year 1, and Year 2. Results: The mean age was 70.0 ± 5.6 years, and 49.8% were female. Cocoa extract supplementation significantly decreased hsCRP levels compared with placebo, with a between-group difference in yearly percentage change relative to baseline levels of −8.4% (95% CI, −14.1% to −2.3%; nominal P = .008; Holm-adjusted P value = .039). Moreover, cocoa extract increased IFN-γ with a 6.8% (95% CI, 1.5% to 12.2%, nominal P = .011; Holm-adjusted P value = .043) difference in yearly percentage change versus placebo. The effects of cocoa extract on other inflammatory markers were not significant (all adjusted P values >.05). Conclusion: Cocoa extract supplementation significantly decreased hsCRP, supporting a role in modulating the chronic inflammaging process as a potential mechanism underlying its cardio-protective effects, including a 27% reduction in cardiovascular disease death in the COSMOS trial. The biological effect of increased IFN-γ by cocoa extract warrants further exploration.Keywords
Funding Information
- National Institutes of Health (HL157665)
- National Institutes of Health (AG050657, AG071611, EY025623)
This publication has 43 references indexed in Scilit:
- Sex/gender-related differences in inflammagingMechanisms of Ageing and Development, 2023
- Design and baseline characteristics of participants in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS)Contemporary Clinical Trials, 2022
- Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutritionAgeing Research Reviews, 2017
- Dark chocolate attenuates intracellular pro-inflammatory reactivity to acute psychosocial stress in men: A randomized controlled trialBrain, Behavior, and Immunity, 2016
- Inflammaging and Anti-Inflammaging: The Role of Cytokines in Extreme LongevityArchivum Immunologiae et Therapiae Experimentalis, 2015
- Natural cocoa consumption: Potential to reduce atherogenic factors?The Journal of Nutritional Biochemistry, 2015
- The impact of chocolate on cardiovascular healthMaturitas, 2011
- Influence of a cocoa‐enriched diet on specific immune response in ovalbumin‐sensitized ratsMolecular Nutrition & Food Research, 2009
- Intestinal immune system of young rats influenced by cocoa-enriched dietThe Journal of Nutritional Biochemistry, 2008
- Interleukin-10 concentration and coronary heart disease (CHD) event risk in the estrogen replacement and atherosclerosis (ERA) studyAtherosclerosis, 2008